Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Gains from Sales and Divestitures (2021)

Barinthus Biotherapeutics (BRNS) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $514923.0 as the latest value for Q4 2021.

  • For Q4 2021, Gains from Sales and Divestitures changed N/A year-over-year to $514923.0; the TTM value through Dec 2021 reached $514923.0, changed N/A, while the annual FY2021 figure was $514923.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures hit $514923.0 in Q4 2021 for Barinthus Biotherapeutics, roughly flat from $514923.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $514923.0 in Q2 2021 and bottomed at $514923.0 in Q2 2021.